E Fund Management Co. Ltd. Trims Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

E Fund Management Co. Ltd. lessened its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 2.1% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,096 shares of the company’s stock after selling 89 shares during the period. E Fund Management Co. Ltd.’s holdings in Neurocrine Biosciences were worth $540,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. Headinvest LLC bought a new position in shares of Neurocrine Biosciences in the 3rd quarter worth approximately $28,000. Lindbrook Capital LLC boosted its holdings in shares of Neurocrine Biosciences by 85.0% during the 4th quarter. Lindbrook Capital LLC now owns 209 shares of the company’s stock valued at $28,000 after buying an additional 96 shares in the last quarter. EdgeRock Capital LLC purchased a new stake in shares of Neurocrine Biosciences in the 4th quarter worth about $31,000. Benjamin F. Edwards & Company Inc. bought a new position in shares of Neurocrine Biosciences in the 4th quarter worth about $33,000. Finally, Sunbelt Securities Inc. lifted its position in Neurocrine Biosciences by 34.3% during the 3rd quarter. Sunbelt Securities Inc. now owns 325 shares of the company’s stock valued at $37,000 after acquiring an additional 83 shares during the period. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Stock Performance

Shares of NASDAQ NBIX traded down $4.17 during trading on Wednesday, hitting $139.02. The company had a trading volume of 653,593 shares, compared to its average volume of 845,459. Neurocrine Biosciences, Inc. has a 12 month low of $89.04 and a 12 month high of $148.37. The firm has a market capitalization of $13.99 billion, a P/E ratio of 38.30 and a beta of 0.28. The stock has a 50 day simple moving average of $137.72 and a 200 day simple moving average of $129.51.

Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings results on Wednesday, February 7th. The company reported $1.44 EPS for the quarter, topping analysts’ consensus estimates of $1.13 by $0.31. The company had revenue of $515.20 million for the quarter, compared to analysts’ expectations of $518.52 million. Neurocrine Biosciences had a net margin of 18.65% and a return on equity of 17.45%. The firm’s revenue was up 25.0% compared to the same quarter last year. During the same quarter last year, the business earned $0.88 EPS. As a group, analysts predict that Neurocrine Biosciences, Inc. will post 4.78 EPS for the current year.

Insider Activity at Neurocrine Biosciences

In other news, insider Ingrid Delaet sold 5,000 shares of the company’s stock in a transaction dated Thursday, March 21st. The stock was sold at an average price of $145.06, for a total value of $725,300.00. Following the completion of the transaction, the insider now owns 7,507 shares of the company’s stock, valued at $1,088,965.42. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Neurocrine Biosciences news, insider Eric Benevich sold 75,000 shares of the stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $139.38, for a total transaction of $10,453,500.00. Following the completion of the transaction, the insider now owns 40,778 shares of the company’s stock, valued at approximately $5,683,637.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Ingrid Delaet sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, March 21st. The stock was sold at an average price of $145.06, for a total value of $725,300.00. Following the sale, the insider now directly owns 7,507 shares in the company, valued at $1,088,965.42. The disclosure for this sale can be found here. In the last quarter, insiders have sold 177,044 shares of company stock worth $24,399,293. 4.30% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on NBIX shares. Cantor Fitzgerald reiterated an “overweight” rating and set a $155.00 target price on shares of Neurocrine Biosciences in a report on Wednesday, April 10th. Barclays raised their price target on Neurocrine Biosciences from $150.00 to $169.00 and gave the company an “overweight” rating in a report on Thursday, May 2nd. BMO Capital Markets upped their price target on shares of Neurocrine Biosciences from $129.00 to $138.00 and gave the stock a “market perform” rating in a research note on Thursday, May 2nd. Wedbush restated an “outperform” rating and set a $147.00 price objective on shares of Neurocrine Biosciences in a research note on Wednesday, April 17th. Finally, The Goldman Sachs Group upped their target price on shares of Neurocrine Biosciences from $134.00 to $153.00 and gave the stock a “buy” rating in a research note on Thursday, January 25th. Six investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $147.88.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.